BioCatalystWatch
EVAXWorkspace / EVAX / OverviewCompany library
Price
Market cap
Next catalystDec 13, 2026EVX-04 · Data readoutCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

EVX-04

Vaccine

ERV-derived tumor antigen fragments

Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

EVX-04

Vaccine

ERV-derived tumor antigen fragments

Upcoming / outlook

  • Timing and evidence

Other pipelines

Vaccine

CMV glycoprotein B (gB) × Novel CMV B-cell antigens × Novel CMV T-cell epitopes

Patient-specific neoantigens

PreINDP1P2P3FilingApproved

Autoantibodies (unspecified)

Essential S. aureus toxins × Major S. aureus virulence factors

Partner / License out

History / paused

Personalized neoantigens × ERV-derived tumor antigens

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

EVAX PR & News

PR & News

EVAX SEC archive